Figure 2 | Laboratory Investigation

Figure 2

From: Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice

Figure 2

The effect of MR16-1 treatment on plasma IL-6 levels and hepatic IL-6/GP130-related gene expression in MCD diet-fed mice. (a) Plasma IL-6 levels were measured. Mean±s.e. data from each MCD diet-fed group (n=5 per group) are plotted at 8 weeks. (b) P-STAT3, STAT3, p-Akt, Akt, p-AMPK and AMPK levels were evaluated by immunoblot analysis of livers obtained from three mice per group after 8 weeks. To control for loading, the blot was stripped and reprobed for β-actin. P-STAT3/t-STAT3, P-Akt/t-Akt and p-AMPK/t-AMPK ratios in each group were also expressed as fold change of control IgG-treated mice (*P<0.05). (c) Plasma SAA levels were measured. Mean±s.e. data from each group (n=5 per group) are plotted at 8 weeks. (d) mRNA levels of hepatic SOCS3 were determined by quantitative real-time PCR analysis after 8 weeks of treatment. Results were normalized to GUS expression and then expressed as fold change relative to gene expression in controls. Mean±s.e. data from each MCD diet-fed group (n=5 per group) (*P<0.05).

Back to article page